Ziconotide (Prialt)
FDA-approved intrathecal analgesic derived from cone snail venom for severe chronic pain
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
2.4 – 19.2 mcg/day
2.4 mcg/day
Starting point
Increase up to 2.4 mcg/day per step
Until pain is controlled
Up to 19.2 mcg/day
Ongoing/maintenance
Compound profile
Scientific & efficacy data
Healing & Recovery
Peptide profile
Strong human trials
Ziconotide (Prialt)
2.4 mcg/day · Continuous intrathecal infusion
Molecular formula
C102H172N36O32S7
- Mol. weight
- 2639.2 Da
- CAS number
- 107452-89-1
- PubChem
- 16135415
- Developed · 2004
- Elan Pharmaceuticals
Elan Pharmaceuticals (now TerSera Therapeutics)
Amino acid sequence
25-amino acid peptide with 3 disulfide bridges (synthetic ω-conotoxin MVIIA)Pain Relief
An N-type calcium channel antagonist delivered into the cerebrospinal fluid, approved for severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment — including intrathecal morphine [6]. That last clause is the point: this is what is tried when intrathecal morphine has already failed.
Opioid Alternative
Genuinely non-opioid, and that matters — it acts on calcium channels rather than opioid receptors, and the label states therapy can be interrupted or stopped abruptly without evidence of withdrawal effects [6]. Two things it does not eliminate: patients must NOT be abruptly withdrawn from their existing opiates but tapered over weeks and replaced with an equivalent oral dose [6], and the label warns that patients may become unresponsive or stuporous on ziconotide [6]. Trading opioid risks for a boxed neuropsychiatric warning is a trade, not an escape.
Neuropathic Pain
The approved indication is severe chronic pain in a refractory population rather than any specific pain syndrome, and the label does not single out neuropathic pain [6]. The mechanism — blocking N-type calcium channels on primary nociceptive afferents in the dorsal horn — is the basis for expecting a neuropathic effect, but the indication is broader and less specific than that reasoning implies.
Dosing
How much do I take?
2.4 – 19.2 mcg/day
2.4 – 19.2 mcg/day
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for severe chronic pain management & opioid-refractory neuropathic pain
Best for
Severe chronic pain management
Ziconotide (Prialt) is particularly well-suited for individuals focused on severe chronic pain management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Opioid-refractory neuropathic pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on opioid-refractory neuropathic pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cancer-related intractable pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on cancer-related intractable pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing systemic opioid dependence
Ziconotide (Prialt) is particularly well-suited for individuals focused on reducing systemic opioid dependence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Ziconotide (Prialt) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intrathecal infusion by implanted or external microinfusion pump — NOT for intravenous use
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
2 common side effects · 2 serious
PRIALT carries a BOXED WARNING for neuropsychiatric adverse reactions: severe psychiatric symptoms and neurological impairment may occur, every patient must be monitored frequently for cognitive impairment, hallucinations or changes in mood or consciousness, and therapy must be discontinued if serious neurological or psychiatric signs appear.
It is CONTRAINDICATED in anyone with a pre-existing history of psychosis [6]. The reported rates are specific: hallucinations 12%, paranoid reactions 3%, hostility 2%, delirium 2%, psychosis 1%, manic reactions 0.4%.
The label also states that ziconotide may cause or worsen depression with risk of suicide in susceptible patients, and that the placebo-controlled trials showed a HIGHER incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo [6].
Beyond the box, the label warns about meningitis — patients and carers must know the signs, including fever, headache, stiff neck, altered mental status, nausea or vomiting and occasionally seizures — about patients becoming unresponsive or stuporous, about elevations in creatine kinase requiring periodic monitoring, and about opiate withdrawal: patients must NOT be abruptly withdrawn from their opiates but tapered over a few weeks and replaced with an equivalent oral dose [6].
Ziconotide itself can be stopped abruptly without withdrawal effects [6].
Every figure above comes from the PRIALT prescribing information, which is the primary document for this compound [6].
The rates the page previously carried — mood changes in '20-50% of patients depending on infusion rate' and cognitive decline requiring dose reduction in 'about 25%' — did not come from the label and had no source attached.
Ziconotide's approved population is narrow: adults with severe chronic pain for whom intrathecal therapy is already warranted and who are intolerant of or refractory to other treatment, including intrathecal morphine [6].
It requires an implanted or external pump and a physician experienced in intrathecal administration; nothing about it is self-administered.
Common side effects · experienced by some users
Dizziness
Most common adverse effect reported in 46% of patients versus 13% placebo in clinical trials
Management: Usually manageable with dose adjustment; may improve with continued therapy
Nausea
Reported in 40% of patients; gastrointestinal effects also include diarrhea (18%) and vomiting (16%)
Management: Antiemetic medications as needed; often improves during dose stabilization
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ziconotide (Prialt)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ziconotide (Prialt) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Baclofen — Intrathecal baclofen may complement ziconotide for mixed pain and spasticity syndromes
- Safe:Gabapentin — Oral gabapentin addresses peripheral neuropathic pain through complementary calcium channel mechanisms
- Safe:Physical Therapy — Rehabilitation combined with intrathecal analgesia optimizes functional recovery outcomes
With medications
- Caution:CNS Depressants — May potentiate central nervous system depression including somnolence and confusion
- Caution:Intrathecal Opioids — Concurrent intrathecal opioids increase risk of serious adverse events including respiratory depression
- Caution:Psychotropic Medications — May exacerbate psychiatric adverse effects including hallucinations and psychosis risk
With supplements
- Safe:Multivitamins — Generally safe to take alongside Ziconotide (Prialt). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs acute response (hours to days)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved (PRIALT, 2004) for the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, including intrathecal morphine
Carries a BOXED WARNING for neuropsychiatric adverse reactions and is contraindicated in anyone with a pre-existing history of psychosis.
Onset of effects
Moderate
(1-2 weeks)
How it works
Ziconotide works like a natural pain-blocking substance that binds to calcium channels in your spinal cord.
Calcium normally helps pain signals travel through your nerves, but ziconotide locks these channels and stops pain messages before they reach your brain.
It's delivered directly into the fluid around your spinal cord through a special pump, which keeps pain relief extremely targeted without affecting your whole body.
The deeper mechanism
Ziconotide is a 25-amino acid synthetic peptide derived from omega-conotoxin MVIIA, a toxin from the Conus magus cone snail.
It acts as a selective antagonist of N-type voltage-gated calcium channels (Cav2.2) located on primary nociceptive nerve terminals in the superficial dorsal horn of the spinal cord.
By blocking these channels, ziconotide prevents calcium influx necessary for synaptic vesicle fusion and neurotransmitter release from pain-signaling A-delta and C fibers.
This blocks pain signal transmission at the spinal cord level without activating opioid receptors, making it suitable for opioid-refractory pain. The CSF half-life of approximately 4.6 hours enables continuous analgesia via intrathecal microinfusion pump delivery.
What to expect
Acute Response (Hours to Days)
What you might notice
- Pain relief may begin within hours of intrathecal infusion initiation;
- CSF half-life is 4.6 hours providing continuous analgesic coverage
What's normal
- Initial response to Ziconotide (Prialt) is beginning at the cellular level
- Different individuals experience Ziconotide (Prialt)'s onset at different rates
- Transient systemic effects from initial Ziconotide (Prialt) exposure are common
What's next
- Maintain consistent Ziconotide (Prialt) administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Titration Period (1-3 Weeks)
What you might notice
- Gradual dose optimization over 21 days with incremental increases;
- progressive pain improvement as therapeutic dose is reached
What's normal
- Ziconotide (Prialt) has achieved stable, long-term homeostatic integration
- Sustained efficacy of Ziconotide (Prialt) remains consistent
- Chronic Ziconotide (Prialt) effects remain stable and predictable
What's next
- Maintain your established Ziconotide (Prialt) protocol for sustained benefits
- Continue periodic monitoring to confirm Ziconotide (Prialt) efficacy
- Review comprehensive Ziconotide (Prialt) response with your provider
Maintenance Therapy (Months to Years)
What you might notice
- Sustained pain relief without tolerance development;
- pump refills every 40-84 days;
- long-term studies show continued efficacy beyond 1 year
What's normal
- Full therapeutic effects of Ziconotide (Prialt) are well-characterized at this point
- Maintenance of Ziconotide (Prialt)'s therapeutic effects is typical
- Tolerance patterns with Ziconotide (Prialt) are generally stable over months
What's next
- Comprehensive assessment of Ziconotide (Prialt) efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Ziconotide (Prialt) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
14 registered studies, 4 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 759 people took part in the studies that actually administered Ziconotide (Prialt). Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer
Clinique Bizet
Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy
Christian Hospital Northeast Northwest
Ziconotide for Non-cancer Pain by Intrathecal Administration
ESTEVE Pharmaceuticals SAS
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Ziconotide (Prialt) is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
How is ziconotide different from opioid pain medications?
Ziconotide works through a completely different mechanism than opioids. It blocks N-type calcium channels at the spinal cord rather than activating opioid receptors. This means it does not cause respiratory depression, does not produce tolerance or physical dependence, and cannot be reversed by naloxone. It provides an alternative for patients who have failed opioid therapy.
Why does ziconotide require intrathecal administration?
Ziconotide is a large peptide (25 amino acids) that cannot cross the blood-brain barrier when given systemically. Intrathecal delivery places the drug directly into the cerebrospinal fluid where it can access its target calcium channels on spinal cord neurons. This route also minimizes systemic side effects while maximizing spinal cord concentrations.
What is the FDA black box warning for ziconotide?
Ziconotide carries a black box warning for neuropsychiatric adverse reactions. Patients may experience severe psychiatric symptoms including hallucinations, psychosis, paranoid reactions, and changes in mental status. It is contraindicated in patients with a pre-existing history of psychosis. Cognitive impairment and reduced consciousness may also occur.
Can ziconotide be used alongside other intrathecal medications?
Ziconotide should be used cautiously with other intrathecal agents. While some practitioners combine it with intrathecal baclofen for mixed pain and spasticity, concurrent use with intrathecal opioids may increase the risk of serious adverse events. The drug should not be mixed with other medications in the same pump reservoir without compatibility data.
How long does it take for ziconotide to provide pain relief?
Pain relief may begin within hours of starting the intrathecal infusion, as the drug's CSF half-life is approximately 4.6 hours. However, optimal pain relief typically requires a gradual titration period of 1-3 weeks, during which the dose is carefully increased based on individual response and tolerability.
What maintenance is required for the intrathecal pump?
The programmable infusion pump requires periodic refills every 40-84 days depending on the drug concentration used and flow rate. Pump battery replacement surgery is needed approximately every 5-7 years. Regular follow-up visits are essential for dose adjustments, pump monitoring, and screening for catheter-related complications including infection.
Further reading
History & related research
History · since 1970
Snake venom transformed into a powerful pain reliever that doesn't addict you.
Ziconotide is a pain medicine discovered from cone snail venom. A scientist named Baldomero Olivera collected snails in the Philippines and noticed their venom had interesting effects.
Read the full history of Ziconotide (Prialt)Studied for
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Ziconotide (Prialt), on one page.